Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neoplasms 3Neoplasm Metastasis 3Glioblastoma 3Central Nervous System Neoplasms 3Sarcoma 2Rectal Neoplasms 2Melanoma 2Gliosarcoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Somatostatinoma 1Solitary Fibrous Tumor, Pleural 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

Temozolomide 13Filgrastim 8Carboplatin 8Radiotherapy 7Magnetic Resonance Spectroscopy 7Etoposide 7Cisplatin 7Cyclophosphamide 6Bevacizumab 6Vincristine 4Thiotepa 4Carmustine 4sargramostim 3Surveys and Questionnaires 3Peripheral Blood Stem Cell Transplantation 3Methotrexate 3Lapatinib 3Irinotecan 3Azacitidine 3veliparib 2alovudine 2aldesleukin 2Tamoxifen 2Radiotherapy, Conformal 2Radiation 2Paclitaxel 2Mental Status and Dementia Tests 2Imatinib Mesylate 2Granulocyte-Macrophage Colony-Stimulating Factor 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ependymoma × vatalanib × Clear all
NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Duke University

Phase 1 Completed
37 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡